Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA3 | O75311 | 1/20 | 0.44 |
| ▸ | GLRB | P48167 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | CTRC | Q99895 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | COMT | P21964 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129283 | 0.83 | SLC22A12 (0.45) | GLRA3GLRBDHODH | |
| SCHEMBL4115492 | 0.81 | GLRA3 (0.49) | GLRA3GLRBALDH1A1HSD17B10GAA | |
| SCHEMBL4113835 | 0.80 | MCL1 (0.49) | GLRA3GLRBALDH1A1DHODHPOLB | |
| SCHEMBL4122027 | 0.79 | GLRA3 (0.69) | GLRA3GLRBALDH1A1LMNAGAA | |
| SCHEMBL4126263 | 0.78 | MEN1 (0.43) | ALDH1A1LMNASMN1; SMN2POLBRAB9A | |
| SCHEMBL4128724 | 0.77 | GLRA3 (0.54) | GLRA3GLRBALDH1A1HSD17B10GAA | |
| SCHEMBL4128242 | 0.74 | SLC22A12 (0.46) | GLRA3GLRBALDH1A1HSD17B10KDM4E | |
| SCHEMBL2789477 | 0.74 | GLRA3 (0.57) | GLRA3GLRBALDH1A1GAASMN1; SMN2 | |
| SCHEMBL28178584 | 0.74 | ALDH1A1 (0.52) | ALDH1A1LMNAALOX12DHODHKDR | |
| SCHEMBL4115482 | 0.74 | SLC22A12 (0.47) | GLRA3GLRBDHODHKDRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| EP-1890993-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR ANTAGONISTS OF GLYR | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006121390-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | WO | claimed |
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| EP-1890993-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR ANTAGONISTS OF GLYR | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006121390-A2 | BENZOIC ACID DERIVATIVES THAT ARE MODULATORS OR AGONISTS OF GLYR | ASTRAZENECA AB (SE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192190-A1 | Benzoic Acid Derivatives that are Modulators or Agonists of GlyR | GLRA1, GLRB, GPBAR1 | GLRA3 6/4885GLRB 2/4885ALDH1A1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.